The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

artaxbiopharma.com

Total Raised

$44.18M

Investors Count

7

Deal Terms

2

Artax Biopharma Funding, Artax Biopharma Valuation & Artax Biopharma Revenue

7 Fundings

Artax Biopharma's latest funding round was a Series C for $26M on January 3, 2022.

Artax Biopharma's valuation in September 2015 was $13.33M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

1/3/2022

Series C

$26M

0

FY undefined

3

2/26/2021

Debt - II

$99M

0

FY undefined

10

4/29/2020

Series B - III

$99M

0

FY undefined

10

8/12/2019

Series B - II

$99M

0

FY undefined

10

9/22/2015

Series B

$99M

$13.33M

0

FY undefined

10

Date

1/3/2022

2/26/2021

4/29/2020

8/12/2019

9/22/2015

Round

Series C

Debt - II

Series B - III

Series B - II

Series B

Amount

$26M

$99M

$99M

$99M

$99M

Investors

Valuation

$13.33M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

3

10

10

10

10

Artax Biopharma Deal Terms

2 Deal Terms

Artax Biopharma's deal structure is available for 2 funding rounds, including their Series B from September 22, 2015.

Round

Series B

Series A

Funding Date

$99M

$99M

Pre-Money Valuation

$99M

$99M

Post-Money Valuation

$99M

$99M

Amount Raised

$99M

$99M

Shares Authorized

Issuance Price

$99M

$99M

Dividend Rate

$99M

Liquidation Preferences

$99M

$99M

Liquidation Price

Participation

Conversion Price

Anti Dilution

$99M

$99M

General Voting

$99M

$99M

Board Voting

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Artax Biopharma Investors

7 Investors

Artax Biopharma has 7 investors. Advent Life Sciences invested in Artax Biopharma's Series C funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

9/22/2015

1/3/2022

4
Series B, Series B - II (2019), Series B - III (2020), Series C (2022)

Venture Capital

United Kingdom

00/00/0000

00/00/0000

Columbus Venture Partners

Subscribe to see more

Venture Capital

Spain

00/00/0000

00/00/0000

Eli Lilly and Company

Subscribe to see more

Corporation

Indiana

00/00/0000

00/00/0000

Belinda Termeer

Subscribe to see more

Angel Investor (Individual)

Massachusetts

00/00/0000

00/00/0000

Sound Bioventures

Subscribe to see more

Venture Capital

Sweden

First funding

9/22/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

1/3/2022

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Columbus Venture Partners

Eli Lilly and Company

Belinda Termeer

Sound Bioventures

Rounds

4
Series B, Series B - II (2019), Series B - III (2020), Series C (2022)

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Type

Venture Capital

Venture Capital

Corporation

Angel Investor (Individual)

Venture Capital

Location

United Kingdom

Spain

Indiana

Massachusetts

Sweden

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.